Cannabis for Multiple Sclerosis

GC
SA
Overseen BySarah A Morrow, MD, MS, FRCPC, FAAN
Age: 18 - 65
Sex: Any
Trial Phase: Phase 2
Sponsor: University of Calgary
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The goal of this clinical trial is to examine the effect of Cannabis components, THC and CBD, on cognition and bladder symptoms in people with Multiple Sclerosis (MS).

Participants will complete questionnaires and cognitive tests. They will be randomly assigned to receive either CBD or THC oil and will take the study drug for 15 weeks.

Are You a Good Fit for This Trial?

This trial is for adults with Multiple Sclerosis who have bladder symptoms scored at least 7 on the NBSS. They must use contraception if applicable, agree to study terms, and have a stable medication routine for bladder issues if they're already being treated.

Inclusion Criteria

I have been on the same NLUTD medication for at least 4 weeks.
I have been diagnosed with Multiple Sclerosis.
I have symptoms of bladder dysfunction with a score of 7 or more.
See 2 more

What Are the Treatments Tested in This Trial?

Interventions

  • Cannabis (THC vs. CBD)

Trial Overview

The trial tests how THC or CBD oils affect cognition and bladder control in MS patients over 15 weeks. Participants will be randomly given either oil and complete cognitive tests and questionnaires throughout the study.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Tetrahydrocannabinol (THC) 25 mgExperimental Treatment1 Intervention
Group II: Cannabidiol (CBD) 50 mgExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Calgary

Lead Sponsor

Trials
827
Recruited
902,000+

Multiple Sclerosis Society of Canada

Collaborator

Trials
17
Recruited
990+